A stage IV high-grade serous ovarian cancer patient carrying ERBB2 amplification and ERBB2 overexpression benefits from late-line pyrotinib treatment - A case report

Sep 23, 2026

Uploaded by Stanley

Ovarian cancer is commonly diagnosed at an advanced stage, and high-grade serous ovarian cancer (HGSOC) accounts for about 70% of cases. ERBB2 overexpression is frequent in HGSOC, while patients with ERBB2 amplification or ERBB2 overexpression lack an established treatment strategy. This report describes a metastatic HGSOC patient harboring ERBB2 amplification and overexpression who, after failure of platinum-based chemotherapy and antiangiogenic therapies, achieved stable disease with 9.5 months progression-free survival on late-line pyrotinib.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages11

Reading Time28 min

AccessFree to download

Abstract

Introduction

Case presentation

Case report SCIENCE PROGRESS | A stage IV high-grade serous ovarian cancer patient carrying ERBB2 ampliﬁcation and ERBB2 overexpression beneﬁts from late-line pyrotinib treatment: A case report | Science Progress 2025, Vol. 108(3) 1–11 © The Author(s) 2025 Article reuse guidelines:
[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/00368504251362310](DOI: 10.1177/00368504251362310)[ ](DOI: 10.1177/00368504251362310)[journals.sagepub.com/home/sci](journals.sagepub.com/home/sci)
| | --- | --- | | Baorang Zhu 1,*, Ying Liu 1,*, Jing Li 1 and Wuwei Yang 1
Abstract
Ovarian cancer (OC), one of the most common gynecological cancers, is usually diagnosed at an advanced stage. High-grade serous ovarian cancer (HGSOC) is a histological subtype of OC that accounts for approximately 70% of all OC cases. erb-b2 receptor tyrosine kinase 2 (ERBB2) overexpression commonly occurs in HGSOC, accounting for 12.5% of stage III and IV HGSOCs. Currently, there is no established treatment strategy for OC patients with ERBB2 ampliﬁcation or ERBB2 overexpression. Whether these patients will beneﬁt from ERBB2 inhibitors remains unclear. Herein, we report a patient with metastatic HGSOC carrying ERBB2 ampliﬁcation and ERBB2 overexpression. Following progression to platinum-based chemotherapy and subsequent antiangiogenic therapies, the patient beneﬁted from late-line pyrotinib treatment, achieving stable disease with a progression-free survival of 9.5 months. Our study provides preliminary clinical evidence supporting pyrotinib as a feasible | | | 1 Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
*These authors contributed equally to this work.
Corresponding authors:
Jing Li, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Email: [lijing19792004@163.com](lijing19792004@163.com)
Wuwei Yang, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Email: [zlwwc307@163.com](zlwwc307@163.com) | | Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://](https://)[ ](https://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access page ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)). treatment option for metastatic HGSOC patients with ERBB2 ampliﬁcation and/or ERBB2 overexpression. Prospective trials of pyrotinib should be conducted in appropriately selected OC populations. Keywords Ovarian cancer, ERBB2, pyrotinib, case report, next-generation sequencing Introduction Ovarian cancer (OC), one of the most common gynecological cancers, represents the leading cause of death from cancers ofthe female reproductive system. 1,2 Approximately 90% of OC cases are classiﬁed as epithelial OC (EOC), typically diagnosed at advanced stages and constituting the most lethal gynecological cancer subtype.3,4 According to a dualistic model, EOCs are classiﬁed into two pathogenic types: Type I tumors are genetically stable, arise from recognizable precursor lesions (e.g. endometriosis), and exhibit indolent behavior; Type II tumors are biologically aggressive, characterized by early metastatic and frequent TP53/BRCA mutations.5,6 High-grade serous OC (HGSOC), a Type II subtype, accounts for approximately 70% of OC cases.3,4 Despite standard treatment involving cytoreductive surgery and platinum-based adjuvant chemotherapy, HGSOC patients exhibit a 5-year survival rate of only 5% to 30% .7 Although novel therapeutic strategies, including poly(ADP-ribose) polymerase inhibitors (P

FAQs

Why was pyrotinib considered for this ERBB2-positive HGSOC patient?

The document states that treatment benefit for ERBB2 amplification or overexpression was unclear, and the report provides clinical evidence of pyrotinib efficacy in such a patient.

What treatments were tried before pyrotinib in the case?

The patient progressed after platinum-based chemotherapy and subsequent antiangiogenic therapies before receiving late-line pyrotinib.

What outcome was reported after starting pyrotinib?

The patient achieved stable disease with a progression-free survival of 9.5 months.

Sep 23, 2026

Uploaded by Stanley